Myoseverin

Myoseverin is a microtubule-binding molecule and angiogenesis inhibitor. Myoseverin can induce the reversible fission of multinucleated myotubes into mononucleated fragments. In addition, Myoseverin exerts anti-angiogenic effects by inhibiting endothelial cell function and endothelial progenitor cell differentiation^[1][2]. In Vitro:Myoseverin (20 μM; 24 h) promotes the fission of multinucleated myotubes into mononucleated fragments with "bead-on-a-string" constriction morphology, and causes disassembly of the microtubule cytoskeleton with microtubules aggregating around the nucleus and fragmenting in mouse C2C12 myotubes^[1].
Myoseverin (20 μM; 24 h) promotes DNA synthesis and colony formation, and regulates the expression of more than 93 genes, involving extracellular matrix remodeling, growth factors, immunomodulatory pathways, etc in mouse C2C12 myotubes^[1].
Myoseverin (0-80 μM; 1-7 d) inhibits cell proliferation (IC₅₀: 8 μM) in a reversible manner and suppresses cell migration in human umbilical vein endothelial cells^[2].
Myoseverin (0-80 μM; 7 d) reduces the differentiation of endothelial progenitor cells into adherent cells in human cord blood mononuclear cells^[2].
Myoseverin (0-20 μM; 7 d) inhibits the acetylated low-density lipoprotein (ac-LDL) uptake ability and the expression of endothelial markers (KDR, CD31, vWF) in endothelial progenitor cells^[2]. In Vivo:Myoseverin (0-10 μg; topical application; single dose) inhibits in vivo angiogenesis in the chick chorioallantoic membrane model^[2].